The inclusion of relevant RCTs and observational studies added to the existing evidence base, while the evaluation of major cardiovascular disorders, such as myocardial infarction, myocardial ischemia, stroke, and cardiovascular death provided a deeper understanding of the specific effects of SGLT2 inhibitors on cardiovascular outcomes [35,36]. This evidence concerns the gene SLC5A2 and Stroke.